Aprepitant
FDA-approved product (capsule, oral), marketed as Aponvie, Aprepitant, Cinvanti and 1 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cancer
- Chemotherapy-induced nausea and vomiting
- Nausea
- Nausea and vomiting
- Post operative nausea and vomiting
- Vomiting
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other antiemetics
- FDA pharmacologic class
- Substance P/Neurokinin-1 Receptor Antagonist FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA56.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli42.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae39.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis57.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Aprepitant with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Etrasimod ArginineExisting use: Ulcerative colitis64.1% AI-predicted activityagainst MRSANo documented evidence found
- MethotrexateExisting use: Acute lymphoblastic leukemia, Adenoma, Arthritis and 21 more64.1% AI-predicted activityagainst MRSA50+ registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more63.6% AI-predicted activityagainst MRSA50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome63.6% AI-predicted activityagainst MRSA6 registered studies
- Nafarelin AcetateExisting use: Endometriosis63.6% AI-predicted activityagainst MRSA12 registered studies
- Pafolacianine SodiumExisting use: Other diagnostic agents63.6% AI-predicted activityagainst MRSA1 registered study
- Vinorelbine TartrateExisting use: Cancer, Neoplasm63.6% AI-predicted activityagainst MRSA50+ registered studies
- Ibrexafungerp CitrateExisting use: Vulvovaginal candidiasis63.5% AI-predicted activityagainst MRSANo documented evidence found
- Gonadorelin AcetateExisting use: Gonadotropin-releasing hormones, Tests for fertility disturbances63.4% AI-predicted activityagainst MRSA50+ registered studies
- Icatibant AcetateExisting use: Angioedema, Hereditary angioedema63.4% AI-predicted activityagainst MRSA33 registered studies
- LonafarnibExisting use: Hutchinson-Gilford progeria syndrome, Laminopathies, Progeria63.3% AI-predicted activityagainst MRSA39 registered studies
- LypressinExisting use: Vasopressin and analogues63.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)
NCT00092196 · start 2002-12-01
Registered record
- Registry ID
- NCT00092196
- Conditions
- Nausea; Vomiting; Breast Neoplasms
- Interventions
- MK0869, aprepitant / Duration of Treatment: 3 days
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2002-12-01
- Completion
- 2004-12-01
- Enrolment
- 820
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNausea; Vomiting; Breast NeoplasmsInterventionMK0869, aprepitant / Duration of Treatment: 3 daysPhasePhase 3Registry statusCompletedTreatment of Patients With Major Depressive Disorder With MK0869 (0869-073)
NCT00042029 · start 2002-06-18
Registered record
- Registry ID
- NCT00042029
- Conditions
- Major Depressive Disorder
- Interventions
- MK0869, aprepitant; Comparator: placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2002-06-18
- Completion
- 2003-10-03
- Enrolment
- 324
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMajor Depressive DisorderInterventionMK0869, aprepitant; Comparator: placeboPhasePhase 3Registry statusCompletedTreatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)
NCT00035048 · start 2001-11-21
Registered record
- Registry ID
- NCT00035048
- Conditions
- Major Depressive Disorder
- Interventions
- aprepitant; Comparator: placebo (unspecified)
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2001-11-21
- Completion
- 2003-12-31
- Enrolment
- 540
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMajor Depressive DisorderInterventionaprepitant; Comparator: placebo (unspecified)PhasePhase 3Registry statusCompletedTreatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)
NCT00034983 · start 2001-10-29
Registered record
- Registry ID
- NCT00034983
- Conditions
- Major Depressive Disorder
- Interventions
- aprepitant; Comparator: paroxetine HCL
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2001-10-29
- Completion
- 2003-12-29
- Enrolment
- 900
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMajor Depressive DisorderInterventionaprepitant; Comparator: paroxetine HCLPhasePhase 3Registry statusCompletedTreatment of Patients With Major Depressive Disorder With MK0869 (0869-059)
NCT00035009 · start 2001-09-20
Registered record
- Registry ID
- NCT00035009
- Conditions
- Major Depressive Disorder
- Interventions
- MK0869, aprepitant; Comparator: paroxetine HCL
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2001-09-20
- Completion
- 2004-03-24
- Enrolment
- 468
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMajor Depressive DisorderInterventionMK0869, aprepitant; Comparator: paroxetine HCLPhasePhase 3Registry statusCompleted